Mepha

Executive Summary

Mepha, a Swiss pharmaceutical company founded in 1947 and headquartered in Basel, operates as a wholly-owned subsidiary of Teva Pharmaceutical Industries. The company specializes in the development, manufacturing, and commercialization of high-quality generic medicines, primarily serving patients and healthcare systems in Switzerland and other European markets. As a key player in the generic drug industry, Mepha leverages Teva's global scale and R&D capabilities to offer affordable therapeutic alternatives. With a strong foothold in Switzerland and a growing presence across Europe, Mepha is well-positioned to benefit from increasing demand for cost-effective medications and patent expirations of branded drugs. The company's commitment to quality and regulatory compliance ensures a steady pipeline of new product launches, contributing to its sustainable growth.

Upcoming Catalysts (preview)

• Q3 2026Launch of generic version of a top-selling cardiovascular drug expected to lose patent exclusivity in Europe70% success
• Q4 2026Expansion into biosimilars through strategic partnership or in-house development50% success
• Q2 2026Receipt of Swissmedic approval for a new generic product line (e.g., oncology or CNS)65% success